Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Antonio Gutiérrez, Izaskun Zeberio, Pilar Martinez-Barranco, Francisco Javier Peñalver, Sandra Pérez, Daniel Morillo, Xabier Mart N Martitegui, Concepción Nicolás, Ainara Ferrero, Ana Jiménez Ubieto, Mariana Bastos-Oreiro, Julio Dávila-Valls, Maria Victoria Calle Gordo, María Pérez Sala, Guillermo Rodríguez Garcia, Aranzazu Alonso Alonso, Ana Garcia Noblejas, Diana Sanchez Arguello, Teresa Knight Asorey, Maria Angeles Fernandez Fernandez, Javier López Marin, Jaime Perez de Oteyza, Sonia González De Villambrosia, Elena Perez Ceballos, Alejandro Marin, Belén Navarro, Ruben Fernandez Alvarez, Pilar Gómez, Jose Antonio Hueso, Maria Jesus Penarrubia Ponce, Pilar Bravo, Daniel García Belmonte, Haridian De La Nuez Melian, Sara Nistal, Pau Abrisqueta Costa, Fernanda Ibañez, Luis Palomera, Eva Donato, Andrea Provencio Rincon, Maria Stefania Infante, Eva Gonzalez Barca

Blood (2024) 144 (Supplement 1): 2356.

https://doi.org/10.1182/blood-2024-210868

Published: 2024

Journal Articles

Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo

Almudena Cabero Martínez, Ana García Bacelar, Begoña Mendibil Esquisabel, Javier Nuñez Cespedes, Ana Jiménez Ubieto, Eukene Gainza Gonzalez, Elena Perez Ceballos, Beatriz De La Cruz, Ana Garcia Noblejas, Paula Fernández-Caldas, Norma C. Gutierrez, Blanca Sánchez-González, Rocío Figueroa Mora, Alberto Lopez Garcia, Daniel García Belmonte, Maria Sanchez de Castro, Estefania Cerezo Velasco, Xabier Martin Martitegui, Hugo Daniel Luzardo Henríquez, Jordina Rovira, Luis Antonio Lopez Gomez, Jackeline Solano, Ana Torres Tienza, Maria Stefania Infante, Raquel Santiago Alonso, Raquel Del Campo, Dunia De Miguel Llorente, Alicia Roldán-Pérez, Emilia Pardal, Beatriz Gonzalez Mena, Miguel Ángel Rodríguez Gil, Nazaret Domínguez Velasco, Albert Blanco Juan, Maria Alejandra Blum Dominguez, Javier López Marin, María Peñarrubia-Ponce, Mariana Bastos-Oreiro, Alejandro Martín García-Sancho

Blood (2024) 144 (Supplement 1): 1708.

https://doi.org/10.1182/blood-2024-198904

Published: 2024

Journal Articles

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Blood (2024) 144 (Supplement 1): 3109.

https://doi.org/10.1182/blood-2024-207895

Published: 2024

Journal Articles

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Blood (2023) 142 (Supplement 1): 4870.

https://doi.org/10.1182/blood-2023-186594

Published: 2023

Journal Articles

Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

Mariana Bastos-Oreiro, Ana Jimenez-Ubieto, Sonia González de Villambrosia, Raul Cordoba, Elena Pérez Ceballos, EVA Maria DONATO Martin, Ana Muntañola Prat, Hugo Daniel Luzardo Henriquez, Lourdes Escoda, Maria Jesús Peñarrubia, María Pozas, Alberto Lopez-Garcia, Daniel Garcia, Emilia Pardal, Claudia Salazar Lozada, Alejandro Martín García-Sancho

Blood (2022) 140 (Supplement 1): 9501–9503.

https://doi.org/10.1182/blood-2022-166213

Published: 2022

Journal Articles

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Blood (2022) 140 (Supplement 1): 9342–9344.

https://doi.org/10.1182/blood-2022-163165

Published: 2022

Journal Articles

Salvage Treatment with Ofatumumab and ESHAP (O-ESHAP) for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma After First-Line Chemotherapy: Interim Analysis of a Phase II Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Carmen Martinez, MD, Mercedes Rodriguez-Calvillo, María José Terol, MD, PhD, Blanca Xicoy, MD, PhD, Ramón García-Sanz, Elena Perez-Ceballos, Alberto Cantalapiedra, Eva Domingo-Domènech, MD, Miguel Hernández, Antonia Sampol, MD, Manuel Espeso, Javier Briones, MD, Javier Lopez, Anna Sureda, MD

Blood (2012) 120 (21): 1630.

https://doi.org/10.1182/blood.V120.21.1630.1630

Published: 2012

Journal Articles

Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis

Javier Corral, David Hernandez-Espinosa, Jose Manual Soria, Rocio Gonzalez-Conejero, Adriana Ordonez, Jose Ramon Gonzalez-Porras, Elena Perez-Ceballos, Ramon Lecumberri, Ignacio Sanchez, Vanessa Roldan, Jose Mateo, Antonia Minano, Marcos Gonzalez, Ignacio Alberca, Jordi Fontcuberta, Vicente Vicente

Blood (2007) 109 (10): 4258–4263.

https://doi.org/10.1182/blood-2006-08-040774

Published: 2007

NARROW

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Salvage Treatment with Ofatumumab and ESHAP (O-ESHAP) for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma After First-Line Chemotherapy: Interim Analysis of a Phase II Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only